Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing net income by the combination of dilutive potential common stock, comprised of shares issuable under the Company’s share-based compensation plans, and the weighted average number of common shares outstanding during the reporting period. Dilutive common share equivalents include the dilutive effect of in-the-money share-based awards, which are calculated based on the average share price for each period using the treasury stock method. Under the treasury stock method, when share-based awards are assumed to be exercised, (a) the exercise price of a share-based award and (b) the amount of compensation cost, if any, for future services that the Company has not yet recognized, are assumed to be used to repurchase shares in the current period.


	Three Months Ended March 31,
(in thousands, except per share amounts)	2026		2025
Net income	$	6,067	$	3,171
Weighted average common shares outstanding – Basic	1,888		1,886
Incremental shares outstanding assuming the exercise of dilutive SARs (share-settled)	6		9
Weighted average common shares outstanding – Diluted	1,894		1,895
Basic earnings per common share	$	3.21	$	1.68
Diluted earnings per common share	$	3.20	$	1.67

There were 5 thousand and no potential shares excluded from the computation of diluted earnings per share for the three-month periods ended March 31, 2026 and 2025, respectively, due to the out-of-the-money status of the related share-based awards.

The Company historically has adopted employee stock award plans under which restricted stock, options or stock appreciation rights ("SARs") exercisable for the Company's stock may be granted to key employees or directors of the Company. There is currently one active plan from which the Company may grant share-based awards. The awards eligible to be granted under the plan are limited to SARs, and the maximum aggregate number of shares of common stock of the Company available pursuant to the plan for the grant of SARs is 250 thousand shares. SARs give the holder the right to receive stock equal to the appreciation in the value of shares of stock from the grant date for a specified period of time, and as a result, are accounted for as equity instruments.

As of March 31, 2026, the only outstanding awards under the plan were SARs, which expire within seven years or less from the date of grant. All outstanding SARs vest and are exercisable within five years or less from the date of grant, and all SARs issued to date have been share-settled only. There have been no stock options or SARs granted where the exercise price was less than the market price on the date of grant.


(in thousands, except weighted average exercise price and average remaining contractual term)	Number Of Shares	Weighted Average Exercise Price		Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Outstanding as of January 1, 2025	28	$	154.74	3.90	$	2,312
SARs granted	5	246.75
SARs exercised	(9)	158.04
Outstanding as of December 31, 2025	24	$	170.67	3.91	$	2,312
SARs granted	—	—
SARs exercised	(1)	162.55
Outstanding as of March 31, 2026	23	$	171.21	3.90	$	1,178

Exercisable as of March 31, 2026	21	$	173.78	3.94	$	1,033

Unvested as of March 31, 2026	2	$	144.60	3.45	$	145